Pharvaris N.V. - Ordinary Shares (PHVS)

On our desk, the valuation narrative for Pharvaris is tightly bound to the successful execution of the deucrictibant pipeline. With a market cap hovering around $2.5 billion and a share price sitting near $36.27, the market has clearly priced in high expectations for the Phase 3 CHAPTER-3 topline data anticipated in Q3 2026. However, we are watching the cash burn closely; although the €318 million reported at the end of June 2026—bolstered by the $132.3 million underwritten offering—extends their runway safely into 2028, any unexpected delays in the FDA PDUFA action date set for April 23, 2027, or the parallel EMA review could trigger immediate volatility.

Watching the technical charts and recent institutional analyst actions, PHVS is showing textbook strength within a medium-term rising trend channel. RBC Capital recently reiterated its Outperform rating and raised its price target to $52, reflecting growing buy-side confidence. The positive volume balance—where volume is noticeably heavier on up days compared to down days—points to robust accumulation by institutional players. For market participants tracking momentum, the break through previous resistance around $28.75 has cleared the immediate overhead chart resistance, leaving strong technical tailwinds as we approach late 2026 catalysts.

From a clinical protocol standpoint, evaluating Pharvaris requires looking closely at their transition from injectable standards of care to oral bradykinin B2 receptor antagonists. Their strategy to deliver 'injectable-like efficacy' with the convenience of oral administration for both on-demand (IR capsules) and prophylactic (XR tablets) treatments represents a major potential shift in managing hereditary and acquired angioedema. As clinicians, we are particularly interested in seeing how well the efficacy and safety data from trials like RAPIDe-1 through 3 and CREAATE translate into real-world utility during the ongoing Expanded Access program and upcoming regulatory evaluations.